Evidence map›Paper›PMID 28418867›Full record

ArticleOncotarget2017

Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MSC DNA methylation in endoscopic biopsies.

Francesca Pirini, Sassan Noazin, Martha H Jahuira-Arias, Sebastian Rodriguez-Torres, Leah Friess, Christina Michailidi, Jaime Cok, Juan Combe, Gloria Vargas, William Prado and 12 more

Open access · diamondAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Gut and liver · 2023
    Article
  8. Article
  9. Role of ELMO1 in inflammation and cancer-clinical implications.Cellular oncology (Dordrecht, Netherlands) · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Feasibility of MethylatedFrontiers in oncology · 2021
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 6 countries.

Francesca PiriniBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Sassan NoazinThe Johns Hopkins University, Bloomberg School of Public Health, Department of International Health, Baltimore, MD, USA.
Martha H Jahuira-AriasThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Sebastian Rodriguez-TorresThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Leah FriessThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Christina MichailidiThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Jaime CokHospital Nacional Cayetano Heredia, Pathology Department, Lima, Perú.
Juan CombeInstituto Nacional de Enfermedades Neoplásicas, Gastroenterology Department, Lima, Perú.
Gloria VargasHospital Nacional Arzobispo Loayza, Gastroenterology Department, Lima, Perú.
William PradoHospital Nacional Dos de Mayo, Gastroenterology Department, Lima, Perú.
Ethan SoudryThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Jimena PérezThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Tikki YudinThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Andrea MancinelliThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Helen UngerThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Carmen Ili-GangasLaboratory of Molecular Pathology, Department of Pathological Anatomy, School of Medicine, Universidad de La Frontera, Temuco, Chile.
Priscilla Brebi-MievilleLaboratory of Molecular Pathology, Department of Pathological Anatomy, School of Medicine, Universidad de La Frontera, Temuco, Chile.
Douglas E BergWashington University Medical School, Department of Molecular Microbiology, St Louis, MO, USA.
Masamichi HayashiThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
David SidranskyThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Robert H GilmanThe Johns Hopkins University, Bloomberg School of Public Health, Department of International Health, Baltimore, MD, USA.
Rafael Guerrero-PrestonThe Johns Hopkins University, School of Medicine, Otolaryngology Department, Head and Neck Cancer Research Division, Baltimore, MD, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversidad de La Frontera · CLHospital Nacional Cayetano Heredia · PEHospital Nacional Dos de Mayo · PEInstituto Nacional de Enfermedades Neoplásicas · PEIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITUniversity of California, San Diego · US

Funding

INTEGRATED DEVELOPMENT OF NOVEL MOLECULAR MARKERSU01CA084986 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 1999 to 2014
$33.8M
Epigenomic Markers of HNSCC Survival Across Ethnic GroupsK01CA164092 · NCI · JOHNS HOPKINS UNIVERSITY · PI GUERRERO-PRESTON, RAFAEL · 2011 to 2014
$530k
NOVEL TRANSPOSONS AND PLASTICITY ZONES OF HELICOBACTER PYLORIR21AI088337 · NIAID · WASHINGTON UNIVERSITY · PI BERG, DOUGLAS EUGENE · 2010 to 2011
$416k
HELICOBACTER PYLORI GENOME SEQUENCE EVOLUTIONR21AI078237 · NIAID · WASHINGTON UNIVERSITY · PI BERG, DOUGLAS EUGENE · 2009 to 2010
$266k
Medical Research Council MR/K007467/1NCI NIH HHS K01 CA164092NCI NIH HHS U01 CA084986NIAID NIH HHS R21 AI078237NIAID NIH HHS R21 AI088337
6 · The paper itself

Abstract

Clinically useful molecular tools to triage gastric cancer patients are not currently available. We aimed to develop a molecular tool to predict gastric cancer risk in endoscopy-driven biopsies obtained from high-risk gastric cancer clinics in low resource settings.We discovered and validated a DNA methylation biomarker panel in endoscopic samples obtained from 362 patients seen between 2004 and 2009 in three high-risk gastric cancer clinics in Lima, Perú, and validated it in 306 samples from the Cancer Genome Atlas project ("TCGA"). Global, epigenome wide and gene-specific DNA methylation analyses were used in a Phase I Biomarker Development Trial to identify a continuous biomarker panel that combines a Global DNA Methylation Index (GDMI) and promoter DNA methylation levels of IRF4, ELMO1, CLIP4 and MSC.We observed an inverse association between the GDMI and histological progression to gastric cancer, when comparing gastritis patients without metaplasia (mean = 5.74, 95% CI, 4.97-6.50), gastritis patients with metaplasia (mean = 4.81, 95% CI, 3.77-5.84), and gastric cancer cases (mean = 3.38, 95% CI, 2.82-3.94), respectively (p < 0.0001). Promoter methylation of IRF4 (p < 0.0001), ELMO1 (p < 0.0001), CLIP4 (p < 0.0001), and MSC (p < 0.0001), is also associated with increasing severity from gastritis with no metaplasia to gastritis with metaplasia and gastric cancer.Our findings suggest that IRF4, ELMO1, CLIP4 and MSC promoter methylation coupled with a GDMI>4 are useful molecular tools for gastric cancer risk stratification in endoscopic biopsies.

Indexed as

Adaptor Proteins, Signal TransducingAdenocarcinomaAdolescentAdultAgedAged, 80 and overBasic Helix-Loop-Helix ProteinsBiomarkers, TumorBiopsyCarrier ProteinsDNA MethylationEarly Detection of CancerFemaleGastroscopyGenome-Wide Association StudyHumansAdaptor Proteins, Signal TransducingBasic Helix-Loop-Helix ProteinsBiomarkers, TumorCarrier ProteinsCLIP4 protein, humanELMO1 protein, humanInterferon Regulatory Factor-4Interferon Regulatory FactorsMembrane ProteinsMSC protein, humanELMO1epigenome-wide DNA methylation analysisglobal DNA methylation indexIRF4translational epigenomics

Identifiers

PMID28418867
PMCPMC5503549
OpenAlexW2595857725

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.